
Pharma stocks soar after US midterm elections
pharmafile | November 8, 2018 | News story | Business Services, Manufacturing and Production | Shares, Stock, Trump, biotech, pharma, stock market
Despite the threat of a bipartisan pricing plan, pharma stocks have soared after the announcement of the results of the US midterm elections.
While the Republicans retained control of the house, the party lost control of the Senate thus allowing for a slight Democrat majority of 222 in comparison to the GOP’s 196.
However, analysts are taking the result as a win. Andrea Harris, an analyst at Height Capital Markets commented in suggesting although the industry may be concerned about “headline risk ahead […the] Republican Senate and pharma-friendly Democrats will prevent disruptive policy change.”
Meanwhile RBC Capital Markets’ Brian Abrahams suggested that a political stalemate is the most likely situation, as he described the deadlock as a “best-case scenario”. Either way the midterms call into question the future of the pricing plan.
Nevertheless generic drugmakers are most likely to win out overall as the pricing plan promises to boost business for cheaper drugs.
Louis Goss
Related Content

Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech
Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed …

Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …

Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …





